NewAmsterdam’s Obicetrapib Boosts Approval Potential With Positive Combo Data

The company announced results of the TANDEM study combining the CETP inhibitor with ezetimibe, following successful monotherapy trial data announced in July

hypercholesterolemia — • Source: Shutterstock

NewAmsterdam Pharma Company has added more evidence that its CETP inhibitor obicetrapib is effective at lowering low-density lipoprotein cholesterol (LDL-C) in patients at risk of cardiovascular disease for whom existing therapies are insufficiently effective or tolerated. The results of the Phase III TANDEM trial combining the drug with ezetimibe generated optimism among analysts about the drug’s approvability and blockbuster sales potential.

The company announced positive topline data from TANDEM on 20 November for the fixed-dose combination of obicetrapib 10mg and ezetimibe...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

20 Jun 2025

• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

19 Jun 2025

• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.